ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

10544	Companies
222720	Keywords
151802	Articles
117831	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 03/23/2026 at 21:05, 2 months 17 days ago

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Abivax reports full year 2025 financial results and key business updates, including safety updates, pivotal Phase 3 trial progress, senior leadership appointments, and upcoming milestones. Strong cash position and strategic plans highlighted

Financial Results Abivax Phase 3 Trial Leadership Appointments Business Updates
BRIEF

published on 02/26/2026 at 18:05, 3 months 11 days ago

ABIVAX: Update on Share Capital and Voting Rights

Euronext Paris Share Capital Voting Rights Shares Abivax
BRIEF

published on 02/21/2026 at 12:05, 3 months 16 days ago

Abivax Unveils Promising Obefazimod Data at ECCO 2026

Obefazimod Clinical Efficacy Safety Profile Inflammatory Bowel Disease Anti-Fibrotic Activity
PRESS RELEASE

published on 02/21/2026 at 12:00, 3 months 16 days ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax presents first evidence of anti-fibrotic activity for Obefazimod and new clinical efficacy and safety analyses in inflammatory bowel disease at ECCO 2026

Abivax Obefazimod Clinical Efficacy Inflammatory Bowel Disease Anti-fibrotic
BRIEF

published on 01/26/2026 at 18:05, 4 months 14 days ago

ABIVAX: Share capital and voting rights as of December 31, 2025

Voting Rights Biotechnology Actions AMF Abivax
BRIEF

published on 01/07/2026 at 22:10, 5 months 2 days ago

Abivax unveils its objectives for 2026

Abivax Obefazimod Phase 3 2026 RCH
BRIEF

published on 01/07/2026 at 22:10, 5 months 2 days ago

Abivax Reveals Strategic Plans for 2026

Regulatory Filing Abivax 2026 Outlook Ulcerative Colitis Market Obefazimod Trials Crohn’s Disease Research
PRESS RELEASE

published on 01/07/2026 at 22:05, 5 months 2 days ago

Abivax Provides 2026 Corporate Outlook
Abivax provides 2026 corporate outlook, highlighting market insights, trial progress, and pipeline advancements in treating chronic inflammatory diseases like UC and CD

Abivax Chronic Inflammatory Diseases 2026 Corporate Outlook UC CD
BRIEF

published on 12/18/2025 at 22:10, 5 months 22 days ago

Abivax joins the Nasdaq Biotechnology index

Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology
BRIEF

published on 12/18/2025 at 22:10, 5 months 22 days ago

Abivax Joins Nasdaq Biotechnology Index

Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology Index

Accesswire

Published on 06/10/2026 at 08:00, 1 hour 19 minutes ago

Caledonia Mining Corporation Plc: Motapa Exploration Results
Published on 06/10/2026 at 00:00, 9 hours 19 minutes ago

Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
Published on 06/09/2026 at 23:00, 10 hours 19 minutes ago

NXT Energy Solutions Inc. Announces Results of Annual Meeting of Shareholders
Published on 06/09/2026 at 22:30, 10 hours 49 minutes ago

Gamma Resources Announces Receipt of $604,500 from Warrant Exercises
Published on 06/09/2026 at 21:45, 11 hours 34 minutes ago

Northfield Announces Change of Corporate Name to Juno International Corporation

View all ACCESSWIRE

EQS Group

Published on 06/10/2026 at 09:05, 13 minutes ago

TeamSystem completes its $250 Million AI Investment Plan a year ahead of schedule: further acceleration expected by 2030
Published on 06/10/2026 at 09:04, 14 minutes ago

UNIQA Insurance Group AG: Dividend Announcement
Published on 06/10/2026 at 09:00, 18 minutes ago

Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 06/10/2026 at 09:00, 19 minutes ago

official list notice
Published on 06/10/2026 at 09:00, 19 minutes ago

clearvise AG starts construction of the Tezze solar project in Italy

Les Echos

Published on 06/10/2026 at 07:00, 2 hours 19 minutes ago

Acceleration of Museum Studio's international expansion
Published on 06/09/2026 at 19:30, 13 hours 49 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 06/09/2026 at 18:14, 15 hours 5 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2026
Published on 06/09/2026 at 15:17, 18 hours 1 minute ago

Statement of transactions in own shares from June 1, 2026 to June 5, 2026
Published on 06/09/2026 at 10:37, 22 hours 42 minutes ago

Guillemot Corporation S.A. | Weekly report share buyback from June 1 to June 5 2026

View all LES ECHOS COMFI WIRE